• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA approves first surgical treatment to remove cellulite

FDA approves first surgical treatment to remove cellulite

February 1, 2012
CenterWatch Staff

The FDA has approved Cellulaze, a single-treatment laser that affects the physiological structure of cellulite. Cellulaze, which previously gained approval in the U.K., was developed by Cynosure, a global aesthetic laser manufacturer and creator of the SmartLipo laser.

"Cellulaze is the world's first surgical treatment for cellulite designed to treat women who have struggled to eliminate cellulite through diet and exercise," said Cynosure president and CEO Michael Davin.

Unlike temporary, non-invasive treatments on the market, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, with clinically proven results. In the U.S. alone, patient trials have demonstrated that after two years post-procedure no cellulite has returned to the areas treated.

Four years of clinical data has demonstrated that Cellulaze treatments can increase the thickness of the skin by 25% and increase the elasticity of the skin by 29% at one year.

"We have been extremely fortunate that in Europe the Cellulaze laser treatment has CE mark approval prior to the awaiting FDA approval,” said Neil Wolfenden, Cynosure U.K. managing director. β€œTo-date we have witnessed high patient satisfaction across the board, and impressive national press coverage.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing